Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Sionna Therapeutics, Inc.NASDAQ: SION
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 18.1% from a year ago
Total equity stood at $288.21M at the end of Q1 FY2026, down 18.1% from a year earlier and down 6.1% from the prior quarter.
Context
- Total equity amounted to 94.5% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -18.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 306.83M USD
- Year-over-year change
- +287.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 306.83M | +287.4% |
| FY2024 | 2024-12-31 | (163.71M) | -42.5% |
| FY2023 | 2023-12-31 | (114.88M) | -64.3% |
| FY2022 | 2022-12-31 | (69.92M) | — |
Total Equity vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 total equity of $288.21M is the 7th highest of the 11 companies compared; the peer median is $374.73M.
- Its year-over-year change of -18.1% is the 9th highest of 11, against a peer median of +5.3%.
- Total equity amounts to 94.5% of total assets for SION, versus a peer median of 73.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.06B | +10.2% | -7.8% | 70.8% | |
| Mar 2026 | $941.54M | -7.0% | +44.0% | 91.6% | |
| Sep 2026 | $649.47M | +8.5% | +17.4% | 90.0% | |
| Sep 2026 | $454.3M | +72.1% | +236.5% | 89.9% | |
| Jun 2026 | $407.76M | -12.9% | +98.8% | 76.5% | |
| Mar 2026 | $341.7M | +17.0% | +51.8% | 81.4% | |
| Mar 2026 | $288.21M | -18.1% | — | 94.5% | |
| Sep 2026 | $258.25M | -19.3% | -18.3% | 22.0% | |
| Mar 2026 | $148.62M | +2.0% | +19.3% | 29.5% | |
| Mar 2026 | $13.01M | +137.0% | -32.8% | 3.3% | |
| Jun 2026 | $12.22M | -90.9% | -54.1% | 3.3% | |
| Peer median (excluding SION) | $374.73M | +5.3% | +18.3% | 73.7% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.